Immunohistochemistry for aldosterone synthase CYP11B2 and matrix-assisted laser desorption ionization imaging mass spectrometry for in-situ aldosterone detection.


Journal

Current opinion in nephrology and hypertension
ISSN: 1473-6543
Titre abrégé: Curr Opin Nephrol Hypertens
Pays: England
ID NLM: 9303753

Informations de publication

Date de publication:
03 2019
Historique:
pubmed: 5 1 2019
medline: 29 1 2020
entrez: 5 1 2019
Statut: ppublish

Résumé

Immunohistochemistry for aldosterone synthase (CYP11B2) has markedly provided a comprehensive picture of the adrenocortical diseases, particularly primary aldosteronism. The findings from CYP11B2-immunohistochemistry are consistent with the clinical courses of most patients with primary aldosteronism. We herein review the updated pathophysiology and usefulness of the method for understanding individual patients with different subtypes of primary aldosteronism. After our discovery of aldosterone-producing cell clusters (APCCs) using the immunohistochemistry for CYP11B2, we found possible APCC-to-APA transitional lesions (pAATLs) in a few cases that had been hitherto classified as unilateral hyperplasia or multiple nodules. On the basis of morphological and functional features of pAATLs as well as distributions of somatic mutations within the lesions, we have made a hypothesis that APCC grows to APA via pAATL for one of developmental courses of APA. Recently, we successfully performed in-situ detection of aldosterone on adrenal tissue sections using a state-of-the-art technique, matrix-assisted laser desorption ionization imaging mass spectrometry (MALDI-imaging). This method revealed in-situ synthesis of aldosterone in APCCs and APAs in addition to several other steroids. CYP11B2 immunohistochemistry revealed the pathophysiology of aldosterone production in the past decade, especially formation of APCC in normal adrenals and pAATL that is a possible lesion developing from APCC to APA. The term 'idiopathic hyperaldosteronism' may soon become obsolete.

Identifiants

pubmed: 30608249
doi: 10.1097/MNH.0000000000000487
doi:

Substances chimiques

Aldosterone 4964P6T9RB
Cytochrome P-450 CYP11B2 EC 1.14.15.4

Types de publication

Case Reports Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

105-112

Auteurs

Zhen Zhang (Z)

Department of Uro-Oncology, Saitama Medical University International Medical Center, Saitama, Japan.
Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.

Yuki Sugiura (Y)

Department of Biochemistry.

Tomoatsu Mune (T)

Division of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki.

Mitsuru Nishiyama (M)

Department of Endocrinology, Metabolism & Nephrology, Kochi Medical School, Kochi University, Kohasu, Okoh-cho, Nankoku City, Kochi, Japan.

Yoshio Terada (Y)

Department of Endocrinology, Metabolism & Nephrology, Kochi Medical School, Kochi University, Kohasu, Okoh-cho, Nankoku City, Kochi, Japan.

Kuniaki Mukai (K)

Department of Biochemistry.
Medical Education Center, Keio University School of Medicine, Tokyo.

Koshiro Nishimoto (K)

Department of Uro-Oncology, Saitama Medical University International Medical Center, Saitama, Japan.
Department of Biochemistry.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH